InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
March 17, 2022 07:30 ET
|
InflaRx N.V.
JENA, Germany, March 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
March 08, 2022 07:30 ET
|
InflaRx N.V.
JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
February 28, 2022 07:30 ET
|
InflaRx N.V.
JENA, Germany, Feb. 28, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
February 16, 2022 07:30 ET
|
InflaRx N.V.
In vilobelimab and pembrolizumab combination arm, the three patients enrolled in the first dosing cohort have been treated for 36 days with no safety concernsSteering Committee unanimously voted to...
InflaRx to Present at Annual SVB Leerink Global Health Conference
February 08, 2022 07:30 ET
|
InflaRx N.V.
JENA, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
January 10, 2022 07:30 ET
|
InflaRx N.V.
Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:...
InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events
January 05, 2022 08:00 ET
|
InflaRx N.V.
Presentation at J.P. Morgan Healthcare Conference on January 13thCorporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10thCompany to host virtual R&D...
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa
January 05, 2022 07:30 ET
|
InflaRx N.V.
Phase III study to include a new primary endpoint, the modified HiSCRNew primary endpoint and Phase III trial design to be discussed in detail at virtual R&D event on February 3rdPhase III program...
InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)
November 15, 2021 07:30 ET
|
InflaRx N.V.
Proof of concept established for potential of vilobelimab to reduce use of corticosteroids in AAV patients: vilobelimab demonstrated comparable efficacy to standard of careUse of vilobelimab instead...
InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference
November 11, 2021 07:30 ET
|
InflaRx N.V.
JENA, Germany, Nov. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...